All
Novel Molecular MRI Imaging Technique May Lead to Early Detection of Breast Cancer
August 19th 2015Early detection of metastasis in patients with breast cancer, which is critical for designing effective targeted therapies, has unfortunate limitations with prevalent screening methods. A study published in Nature Communications has shown promise for extending the detection limit of the current clinical imaging technology
DIAPH3 Predicts Breast and Prostate Cancer Responses to Chemotherapies
August 18th 2015A publication in Scientific Reports has identified a novel biomarker, diaphanous-related formin-3 (DIAPH3), which may help predict response to taxane-based chemotherapies in patients with metastatic breast or prostate cancer.
Hodgkin Lymphoma Label for Brentuximab Vedotin Expanded by FDA
August 18th 2015The antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) was recently approved by the FDA as a consolidation therapy following autologous stem cell transplantation (ASCT) in patients who have Hodgkin lymphoma and are at risk of relapse or progression.
All HDAC Inhibitors Are Not Equal for Treating Anaplastic Thyroid Cancer
August 17th 2015A Mayo Clinic Laboratory, which discovered that upregulation of ras homolog gene family member B (RhoB), in combination with paclitaxel results in enhanced antitumor activity, has uncovered the molecular mechanisms underlying combination therapy for anaplastic thyroid cancer (ATC).
FDA Delays Decision for Frontline Nivolumab
August 13th 2015The review period for frontline nivolumab (Opdivo), in patients who have advanced melanoma, recently received an extension of three months by the FDA, in order to allow ample time for review of the additional data submitted by Bristol-Myers Squibb (BMS)
New York Lung Cancer Conference to Prominently Feature Immunotherapy and Targeted Therapies
August 10th 2015On November 7, 2015, some of the leading experts in oncology, together with other oncology healthcare professionals involved in the treatment and management of patients with lung cancer, will gather in Manhattan for the 10th Annual New York Lung Cancer Symposium®.
Underused Ovarian Cancer Treatment Improves Overall Survival
August 7th 2015Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment
Translational Advances Deliver Precision Medicine to NSCLC
August 5th 2015Precision medicine with TKIs and immunotherapies is revolutionizing the treatment of patients with NSCLC. Paul A. Bunn, Jr, MD, head of the Division of Medical Oncology at the University of Colorado, discussed the current translational advances with these agents in a discussion held at this year’s International Lung Cancer Congress.
New Trial Designs Hope to Improve the Discovery of Biomarkers in NSCLC
August 5th 2015Clinical trial designs are experiencing a huge transformation geared toward the discovery and confirmation of new predictive biomarkers for patients who have non-small cell lung cancer (NSCLC), as well as other types of solid tumors.
Rociletinib NDA Completed by Clovis Oncology for EGFR T790M-positive NSCLC
August 4th 2015A new drug application (NDA) was recently submitted for rociletinib (CO-1686) as a treatment for patients who have EGFR T790M-positive metastatic non-small cell lung cancer (NSCLC) following previous administration of an EGFR TKI.
Researchers Identify Five Molecular Prostate Cancer Subtypes That Could Change Risk Assessment
August 3rd 2015Treatment decisions in prostate cancer are still largely guided by the classical diagnostic parameters, including Gleason scoring, TNM classification, and prostate specific antigen (PSA) levels, despite growing evidence that molecular signatures may be useful for assessing risk.
EC Approves Neoadjuvant Pertuzumab Regimen for HER2-Positive Early Breast Cancer
July 31st 2015Pertuzumab (Perjeta), in combination with trastuzumab (Herceptin) and chemotherapy, was approved by the European Commission (EC) as a neoadjuvant therapy for adult patients who have HER2-positive, locally advanced, inflammatory, or early stage breast cancer and are at high risk of recurrence.
E2F4 Predictive of Progression and Immunotherapy Efficacy in Bladder Cancer
July 31st 2015The biomarker E2F4 predicts survival in breast cancer, and an article recently published in the journal Molecular Cancer Research indicates that E2F4 may also predict progression and immunotherapy efficacy in bladder cancer.
Robot-Assisted Surgery Shows Good Survival and Less Blood Loss in Bladder Cancer
July 30th 2015Patients with bladder cancer who undergo robot-assisted radical cystectomy (RARC) appear to have acceptable 5-year survival, according to the largest multi-institutional series to date to collect data on RARC outcomes in this population.
New Genome Characterization Center to Focus on Proteomics Across Tumor Types
July 27th 2015The University of Texas MD Anderson Cancer Center in Houston has been selected as the site for one of two new Genome Characterization Centers (GCCs) funded by the National Cancer Institute (NCI) and National Institute of Health (HHSN261200800001E).